Seer Launches Innovative Proteograph Suite, Transforming Proteomics

Seer Unveils Groundbreaking Proteograph Product Suite

Seer, Inc. (Nasdaq: SEER), based in Redwood City, California, has made a remarkable stride in the field of proteomics by launching its advanced Proteograph Product Suite. This new suite showcases the Proteograph ONE Assay and SP200 Automation Instrument, designed specifically to elevate the capabilities of mass spectrometry-based proteomic research.

Enhancements to Proteomic Workflows

With its latest innovation, Seer aims to tackle the difficulties associated with large-scale proteomic studies. Historically, deep proteomic analyses faced limitations due to insufficient throughput and high associated costs, deterring researchers from pursuing extensive investigations. The Proteograph ONE marked its debut at the American Society for Mass Spectrometry (ASMS) annual conference, where Seer highlighted the significant improvements made to this product suite.

Transformative Benefits of the New Workflow

The Proteograph workflow stands out by processing more than 1,000 samples weekly on a single SP200 instrument. This allows researchers to achieve depth and speed in their proteomic analyses that were previously unattainable. Moreover, by implementing a volume-based pricing model, Seer has considerably reduced the cost of proteomic analysis by approximately 60% compared to its original product offerings.

Impact on Research and Discovery

“The introduction of this advanced workflow is a pivotal moment in the field of proteomics,” stated Omid Farokhzad, Seer’s Chair and CEO. This new approach not only supports a deeper and more reproducible exploration of the proteome but also positions unbiased proteomics as a vital tool for scientific and medical advancements. The enhancements provided by the Proteograph ONE are set to redefine proteomic research, unlocking new possibilities for biomarker discovery and multi-center studies.

Seer’s Participation at the ASMS Conference

As part of its presence at ASMS 2025, Seer and its research partners will reveal critical insights derived from the Proteograph Product Suite, with applications in Alzheimer’s research, cancer studies, and drug development. Attendees can look forward to a seminar featuring leading experts in proteomics, who will share their findings from utilizing the Proteograph ONE workflow.

Testimonials from Leading Researchers

Notable researchers have praised Seer’s technology for its depth and efficiency. Josh Coon, a Professor from the University of Wisconsin-Madison, emphasized that the original Proteograph workflow enabled unparalleled exploration of the plasma proteome. With the Proteograph ONE, he anticipates doubling the throughput and expanding the capabilities of population-scale studies.

Overcoming Challenges in Deep Proteomics

Before the introduction of Seer’s latest suite, accessing large-scale deep proteomic research was challenging due to cost and efficiency limitations. Barry Patti, another esteemed researcher from Washington University, acknowledged how Seer’s technology not only enhances scalability but also improves cost-effectiveness. This progression allows researchers to investigate the proteome's complexity at unprecedented resolutions.

Scientific Presentations at ASMS 2025

Seer and its collaborators will present compelling scientific posters at the ASMS conference, focusing on diverse topics within proteomics:

1. Applying deep, unbiased plasma proteomics to study dementia classification, cognitive decline, and pTau-217 biology
2. Pythia: A fast and accurate search engine for quantitative DIA proteomics
3. Sensitive and comprehensive cellular proteome analysis using automated sample preparation techniques
4. Novel workflows for transforming cancer biomarker discovery
5. Automated quantitative analysis of extensive cancer study cohorts

The Proteograph Product Suite will be available for purchase including instruments, kits, and services starting from June 1. For more detailed inquiries about the new Proteograph ONE Assay and SP200 Automation Instrument, interested parties can visit Seer’s booth or contact them directly.

About Seer, Inc.

Seer, Inc. (Nasdaq: SEER) is dedicated to leading the way in deep, unbiased proteomics, delivering critical scientific insights with unmatched scale and efficiency. They integrate advanced technologies including engineered nanoparticles and streamlined automation, uniquely addressing challenges that traditional proteomic approaches struggle to overcome. Seer's products are intended for research purposes only and are not meant for diagnostic use.

Frequently Asked Questions

What is the Proteograph Product Suite?

The Proteograph Product Suite is Seer’s latest offering designed to provide scalable and efficient proteomic analysis through advanced mass spectrometry techniques.

How does the new workflow improve proteomics?

The new workflow enhances throughput, reduces costs, and increases the depth of proteomic analysis, allowing for a more comprehensive exploration of biological samples.

Where will Seer showcase its new products?

Seer will present its new Proteograph suite during the ASMS 2025 conference, showcasing its innovative capabilities and collaborations.

Why is the Proteograph ONE Assay significant?

The assay represents a major advancement in providing comprehensive and unbiased proteomic data essential for scientific and medical research.

How has Seer addressed previous industry limitations?

Seer’s enhanced workflow minimizes manual handling variability and significantly increases procedure efficiency, overcoming barriers that previously hindered deep proteomic studies.

About The Author

Hello, I'm Thomas Cooper, a financial expert and writer passionate about helping people understand and navigate the financial world. Having a solid financial background and a lot of experience, my area of expertise is simplifying difficult financial ideas into useful, understandable guidance. My goal with my writings and blog entries is to provide you the information and resources you need to make wise financial choices.

I am thrilled to contribute my ideas and engage with a lively investor community at Investors Hangout, where I recently joined the team. My mission is to make finance interesting and approachable so you may take charge of your financial future. I appreciate you coming along on this path to success and financial knowledge.

Contact Thomas Cooper privately here. Or send an email with ATTN: Thomas Cooper as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.